EMEA-000060-PIP02-08-M06
Key facts
Invented name |
Ilaris
|
Active substance |
Canakinumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0141/2013
|
PIP number |
EMEA-000060-PIP02-08-M06
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of juvenile idiopathic arthritis
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000060-PIP02-08-M06
|
Compliance opinion date |
09/10/2015
|
Compliance outcome |
positive
|